Literature DB >> 12077285

Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.

Sixun Yang1, Gerald P Linette, Simonne Longerich, Frank G Haluska.   

Abstract

Anchor residue-modified peptides derived from tumor-associated Ag have demonstrated success in engendering immune responses in clinical studies. However, tumor regression does not always correlate with immune responses. One hypothesis to explain this is that CTL resulting from such immunization approaches are variable in antitumor potency. In the present study, we evaluated this hypothesis by characterizing the activity of tumor-associated Ag-specific CTL. We chose an anchor residue-modified peptide from gp100, G209-2M, and used peptide-pulsed dendritic cells to generate CTL from PBMC of HLA-A2(+) normal donors. The specificities and avidities of the resulting CTL were evaluated. The results demonstrate that CTL generated by G209-2M can be classified into three categories: G209-2M-specific CTL which are cytotoxic only to G209-2M-pulsed targets; peptide-specific CTL which recognize both G209 and G209-2M peptides but not melanomas; and melanoma-reactive CTL which recognize peptide-pulsed targets as well as HLA-A2(+)gp100(+) melanomas. CTL that kill only peptide-pulsed targets require a higher peptide concentration to mediate target lysis, whereas CTL that lyse melanomas need a lower peptide concentration. Increasing peptide density on melanomas by loading exogenous G209 peptide enhances their sensitivity to peptide-specific CTL. High avidity CTL clones also demonstrate potent antimelanoma activity in melanoma model in nude mice. Injection of G209 peptide around transplanted tumors significantly enhances the antitumor activity of low avidity CTL. These results suggest that peptide stimulation causes expansion of T cell populations with a range of avidities. Successful immunotherapy may require selective expansion of the higher-avidity CTL and intratumor injection of the peptide may enhance the effect of peptide vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077285     DOI: 10.4049/jimmunol.169.1.531

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

2.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Authors:  Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

Review 4.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

5.  Vaccines with enhanced costimulation maintain high avidity memory CTL.

Authors:  Sixun Yang; James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

6.  Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load.

Authors:  Mohamed Tarek M Shata; Wolfram Pfahler; Betsy Brotman; Dong-Hun Lee; Nancy Tricoche; Krishna Murthy; Alfred M Prince
Journal:  J Med Primatol       Date:  2006-06       Impact factor: 0.667

7.  Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells.

Authors:  Sixun Yang; Jeffrey Schlom
Journal:  Cancer Immunol Immunother       Date:  2008-08-09       Impact factor: 6.968

Review 8.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

9.  Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity.

Authors:  Ying Ding; See Voon Seow; Chiung Hui Huang; Lee Mei Liew; Yaw Chyn Lim; I Chun Kuo; Kaw Yan Chua
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

10.  Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells.

Authors:  Beatriz M Carreno; Michelle Becker-Hapak; Megan Chan; Wen-Rong Lie; Xiaoli Wang; Ted H Hansen; Gerald P Linette
Journal:  J Immunol       Date:  2012-05-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.